Haleon PLC Director/PDMR Shareholding
20 December 2024 - 2:00AM
RNS Regulatory News
RNS Number : 8157Q
Haleon PLC
19 December 2024
Haleon plc:
Director/PDMR Shareholding
19 December 2024: Haleon plc (the "Company" or
"Haleon") (LSE/NYSE:HLN) today announces notification and public
disclosure in accordance with the requirements of The UK Market
Abuse Regulation of Transactions by Persons Discharging Managerial
Responsibilities ("PDMRs").
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Adrian Morris
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
General Counsel - PDMR
|
|
b)
|
Initial notification
/Amendment
|
Initial
Notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction
monitor
|
|
a)
|
Name
|
Haleon plc
|
|
b)
|
LEI
|
549300PSB3WWEODCUP19
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Ordinary Shares of £0.01
each
|
|
|
|
|
Identification
code
|
GB00BMX86B70
|
|
|
|
|
b)
|
Nature of the
transaction
|
Grant of a 3-year option over
Ordinary Shares under the 2024 Haleon Share Save Plan which will
first become exercisable 1 February 2028.
|
|
c)
|
Price(s) and
volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
£3.00
|
6,150
|
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
|
|
|
|
- Aggregated volume
|
|
|
|
|
|
- Price
|
|
|
|
|
|
e)
|
Date of the
transaction
|
19 December 2024
|
|
f)
|
Place of the
transaction
|
Outside a trading venue
|
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a global
leader in consumer health, with a purpose to deliver better
everyday health with humanity. Haleon's product portfolio spans
five major categories - Oral Health, Pain Relief, Respiratory
Health, Digestive Health and Other, and Vitamins, Minerals and
Supplements (VMS). Its long-standing brands - such as Advil,
Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident,
parodontax and Centrum - are built on trusted science, innovation
and deep human understanding.
For more information, please
visit www.haleon.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
DSHBSBDDXUBDGSC
Haleon (LSE:HLN)
Historical Stock Chart
From Nov 2024 to Dec 2024
Haleon (LSE:HLN)
Historical Stock Chart
From Dec 2023 to Dec 2024
